-
Two local pharmaceutical companies, pharmaceutical business revenue in 2021 exceeds 20 billion yuan
Time of Update: 2022-03-06
On the whole, most multinational pharmaceutical companies have achieved growth in performance driven by new drugs, and their revenue in China has basically remained above the baseline of 20 billion yuan .
-
When the annual keywords flow, there is a future: the underlying logic of big health
Time of Update: 2022-03-06
It is expected that the economic departments (development and reform, industry and information technology) and science and technology departments of the central and local governments will continue to issue policy documents to support the big health industry, especially from the perspective of the whole industry chain (industrial ecology) and the whole technology life cycle, hedging The negative impact of the strict cost control policy makes up for the policy shortcomings of limited livelihood protection .
-
Lilly to develop next-generation ADC therapeutics in $1.7 billion R&D partnership
Time of Update: 2022-03-06
Grant Eli Lilly exclusive rights to develop and commercialize antibody drug conjugates (ADCs) against Eli Lilly's selected targets using ImmunoGen's innovative camptothecin technology platform .
References:References: [1] ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.
-
Legend Bio's CAR-T clinical trial in the United States is suspended, and China's innovative drugs have a long way to go
Time of Update: 2022-03-06
"Marketing approval of its CAR-T product, Cedarquiorenza, delayed by FDA because "FDA needs more time to review information submitted by companies" In August 2020, Cidaki Orenza has already received the first batch of breakthrough therapy designations granted by the China Food and Drug Administration, but Legend Bio still decided to list in the United States first, and then submit a listing application to the Chinese regulatory authorities .
-
Case Interpretation DIP/DRG Dual Pilot Improves the Use Efficiency of Medical Insurance Funds
Time of Update: 2022-03-06
Through the use of DIP/DRG management tools, the hospital provides a starting point for clinical departments to improve the level of discipline construction, realizes the decline of simple diseases and the improvement of diagnosis and treatment of difficult and difficult diseases, and promotes the transformation and upgrading of medical institutions from the development of extension scale to the development of connotation quality.
-
Wang Yaping, former FDA reviewer, commented on PD-1 going overseas
Time of Update: 2022-03-06
Judging from the author's years of experience working with Richard Pazdur, as the head of the most important department of the FDA, he has strong professionalism, high vision, and forward-looking policy formulation, and he does not have any prejudice against Chinese companies.
-
Ten billion market, Top 20 drug sales announced (with list)
Time of Update: 2022-03-02
2019Q1-2021Q4 National sample retail pharmacy drug market scale and year-on-year growth 02Market performance of main categories02 In the drug retail pharmacy market in 2021, Chinese patent medicines will occupy the largest category share, reaching 44.
-
24 Class 1 new drugs have been approved for clinical use!
Time of Update: 2022-03-02
According to public information, SHR7280 is a new oral small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist independently developed by Hengrui Medicine .
-
Former FDA Commissioner Robert Califf to Return, Confirmed by Senate
Time of Update: 2022-03-02
Janet Woodcock said on social media on the day Califf's nomination was confirmed that she would serve as Califf's chief deputy chief and support the work of the new chief .
-
The 46th batch of "Pass Consistency Evaluation" list is here
Time of Update: 2022-03-02
1% 301 varieties that have passed the enterprise has reached 3 86 injections that have passed through 3 companies Data statistics are as of January 31st, and Insight will publish the varieties and other trends that have passed the consistency in the last month every month .
-
Express | Open up a new model of targeted RNA, Janssen reached a cooperation of over 1 billion US dollars
Time of Update: 2022-03-02
On February 17, 2022, Remix Therapeutics announced an R&D collaboration with Janssen, a subsidiary of Johnson & Johnson, to use Remix's REMaster drug discovery platform to develop small molecule therapeutics that modulate RNA processing .
-
National Medical Insurance Bureau: Strive to collect more than 5 kinds of high-value medical consumables in each province by the end of 2022
Time of Update: 2022-03-02
At the recent policy briefing of the State Council, Chen Jinfu, deputy director of the National Medical Security Administration, introduced that the procurement of medicines and high-value medical co
-
After the implementation of DRG/DIP, 3 changes in the drug market will happen soon
Time of Update: 2022-02-22
A direct comparison of the impact of two different payment models on hospitals and medicines First, the substitution rate of generic drugs in pay-per-project hospitals is much lower than that in DPC hospitals, with a gap of nearly 15 percentage points .
-
Development stage and prospect analysis of cell therapy industry in my country
Time of Update: 2022-02-22
Figure 1: Clinical staging of domestic immune cell therapy products Source: Flint Creation Arranged based on public information From the perspective of registration classification, most of the immune cell products are registered according to the category 1 innovative drug registration application, a total of 29, accounting for 81%, are the first products that have not been marketed at home and abroad .
-
Eli Lilly and Evotec sign $1 billion partnership to focus on kidney disease and diabetes
Time of Update: 2022-02-22
The collaboration will leverage Evotec's experience and expertise in metabolic disease, as well as its unique and extensive renal disease patient database, integrated data-driven drug discovery and development platform, to identify and validate promising new targets for therapeutic intervention .
-
Ascletis, Junshi, and Genting share prices collectively break out, how far can the new crown oral drug concept stocks go?
Time of Update: 2022-02-22
In fact, in recent days, the stock prices of many domestic pharmaceutical companies that have deployed oral new crown drugs have generally shown a continuous upward trend .
-
China Pharmaceutical Promotion Association 2021 End-of-Year Inventory Series II: Hot Topics in the Pharmaceutical Innovation Industry
Time of Update: 2022-02-22
2021 is the first year of the country's "14th Five-Year Plan" and a new starting point for a century-long journey . This year, the global anti-epidemic became normalized, and China’s various new cro
-
The State Food and Drug Administration approved the registration of 211 medical device products in December
Time of Update: 2022-02-22
On January 17, the State Food and Drug Administration announced that a total of 211 registered medical device products will be approved in December 2021 .
-
China Pharmaceutical Promotion Association 2021 End-of-Year Inventory Series One: Highlights of Big Coffee's Viewpoints
Time of Update: 2022-02-22
Li Jin, professor of Dongfang Hospital Affiliated to Tongji University and chairman of the anti-tumor drug clinical research committee of our society Fausto Pinto, President of the World Heart Federation, pointed out at the Forum on Cardiovascular Disease Prevention and Innovation in the Health and Hygiene Section of the Service Trade Fair that in the new crown epidemic, cardiovascular disease is still the disease that causes the most deaths and the highest morbidity .
-
2020-2021 U.S. New Drug Approval Update Report
Time of Update: 2022-02-22
Table 1: 2021 Center for Biologics Evaluation and Research (CBER) Approved Biological License Application (BLA) In 2021, the US FDA approved a total of 50 new molecular entity drugs (NMEs) .